Actively Recruiting
Development of Hyperpolarized Xenon-129 and Inert Fluorinated Gas Lung MRI Comparative Pilot Study of Healthy Volunteers and Participants With Pulmonary Disease
Led by The Hospital for Sick Children · Updated on 2026-03-02
30
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying the quality and consistency of lung imaging using two advanced MRI methods Xenon-129 and inert fluorinated gas 19F MRI. This study includes participants with cystic fibrosis CF, asthma, and healthy volunteers to compare changes in lung structure and function among these groups. The goal is to explore these imaging techniques as potential tools for detecting lung diseases more sensitively than standard tests like spirometry. Participants inhale hyperpolarized xenon-129 gas and perfluoropropane, an inert fluorinated gas, both used as contrast agents for lung MRI. Perfluoropropane is inhaled as a mixture with oxygen and does not require hyperpolarization, allowing for possibly easier and extended imaging. The study involves three groups healthy individuals, people with cystic fibrosis, and those with asthma. All participants undergo magnetic resonance imaging and lung clearance index tests. During the study, participants will have lung function and imaging assessments, including measurements of ventilation defect percent to observe differences between groups. They must be able to hold their breath briefly and perform reliable lung function tests. The study monitors lung health over time and compares the imaging results to better understand lung disease changes. Participation includes signing consent and completing the imaging and lung function procedures under medical supervision.
CONDITIONS
Brief Title
Xenon-129 and Inert Fluorinated Gas Lung MRI: Study of Healthy Volunteers and Participants With Pulmonary Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants male and female aged 8 years old and older
- Participants have no smoking history
- For participants with cystic fibrosis or asthma, a clinical diagnosis is necessary and they should be at their baseline level of symptom control
- Participants should have a FEV1%pred value greater than 40%
- Participant understands the study procedures and agrees to participate by signing informed consent or assent
- Participant must be able to hold their breath for 20 seconds or less
- Participant able to perform reproducible pulmonary function tests with consistent FEV1 values
- For the pulmonary exacerbation sub-cohort, children admitted and then discharged on home IV antibiotics may be included
You will not qualify if you...
- Participant is mentally or legally unable to give informed consent or understand study materials
- Participant has a history of cardiovascular disorders such as coronary insufficiency, arrhythmias, or severe hypertension
- Except for the pulmonary exacerbation sub-cohort, participant has had a cold or respiratory infection in the last four weeks
- Participant requires supplemental oxygen or has daytime room air oxygen saturation of 95% or less
- Participant is unable to perform spirometry or plethysmography maneuvers
- Participant is pregnant or breastfeeding
- Participant has conditions preventing MRI such as severe claustrophobia
- Participant has MRI-incompatible devices or metal in the body that cannot be removed, including pacemakers or implanted devices
Research Team
G
Giles Santyr, PhD
S
Sharon Braganza, BSc
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here